Resolve Biosciences raises $71 million

The science start-up was able to convince investors Patient Square Capital and EDBI with its technology.

In a Series B financing round, the start-up Resolve Biosciences from Monheim am Rhein has raised 71 million US dollars. Patient Square Capital led the round. EDBI, PS Capital, Alafi Capital and NRW-Bank also participated. Existing investors have also invested again. According to the company, Resolve Biosciences has now received a total of more than 100 million US dollars.

"This Series B funding is another strong endorsement of our mission, our technology and our team," says co-founder and CEO Jason T. Gammack. Founded in 2020, the company uses molecular mapping to provide scientists with new insights based on a high-resolution view of the spatial biology of single cells. The technology could be used to research important questions in the fields of oncology, neuroscience, infectious diseases and agriculture. The technology would already be used in leading laboratories. These include the German Cancer Research Center (DKFZ).

"With its talented team and proprietary molecular mapping technology, Resolve is leading the way in the new era of single-cell spatial analysis, opening the door to a wave of scientific discovery that will redefine our understanding of disease and lead to new therapies and improved patient outcomes," said Laura Furmanski, Partner and Head of Patient Square Insights at Patient Square Capital.